Enitociclib

A CDK9 inhibitor used in cancer treatment

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (3R)-3-[[2-[[3-(3,5-dimethyl-1H-pyrazol-1-yl)-4-methylphenyl]amino]-9,10-dimethoxy-4-oxo-4H-benzo[g]quinazolin-6-yl]oxy]pyrrolidine-1-carbonitrile | image = Enitociclib.svg | image2 = | tradename = | synonyms = BAY 1143572, VIP152 | CAS_number = 1447010-22-8 | ATC_prefix = | ATC_suffix = | PubChem = 71733754 | ChemSpiderID = 29341882 | UNII = 0K3C1XH2X1 | KEGG = D11457 | ChEMBL = 2103874 | C=27 | H=29 | N=7 | O=3 | smiles = CC1=CC(=C(C=C1NC2=C(C3=C(C=C2)C(=O)N=C(N3)OC4CCNC4C#N)OC)OC)N5C=CC=N5C }}

Enitociclib is a small molecule inhibitor of cyclin-dependent kinase 9 (CDK9), a protein that plays a crucial role in the regulation of transcription and cell cycle progression. It is being investigated for its potential use in the treatment of various types of cancer.

Mechanism of Action

Enitociclib functions by selectively inhibiting CDK9, which is a key component of the positive transcription elongation factor b (P-TEFb) complex. CDK9, in association with cyclin T, phosphorylates the C-terminal domain of RNA polymerase II, facilitating the transition from transcription initiation to elongation. By inhibiting CDK9, enitociclib disrupts this process, leading to reduced transcription of genes that are critical for cancer cell survival and proliferation, particularly those involved in anti-apoptotic pathways.

Clinical Development

Enitociclib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with various malignancies. It has shown promise in preclinical studies and early-phase clinical trials, particularly in hematological malignancies such as acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). The drug is also being explored for its potential in treating solid tumors.

Pharmacokinetics

The pharmacokinetic profile of enitociclib includes its absorption, distribution, metabolism, and excretion characteristics. It is administered orally, and its bioavailability and half-life are subjects of ongoing research to optimize dosing regimens. The drug is metabolized primarily in the liver, and its metabolites are excreted via the renal and biliary systems.

Side Effects

As with many anticancer agents, enitociclib may cause a range of side effects. Common adverse effects observed in clinical trials include fatigue, nausea, and hematological toxicities such as neutropenia and thrombocytopenia. The safety profile of enitociclib is being closely monitored in ongoing studies to better understand its tolerability and to manage potential risks.

Research and Future Directions

Research on enitociclib is focused on understanding its full therapeutic potential and identifying biomarkers that predict response to treatment. Combination therapies with other anticancer agents are also being explored to enhance its efficacy. The development of enitociclib represents a significant advancement in targeted cancer therapy, particularly for patients with tumors that are resistant to conventional treatments.

Related Pages

• Cyclin-dependent kinase
• Cancer treatment
• Targeted therapy
• Hematological malignancy